Crest, Oral-B and Blend-a-med Announce the Launch of Their First Ever Recyclable HDPE Toothpaste Tubes in North America and Europe
Today, Procter & Gamble Oral Care unveils its newest packaging innovation across its leading toothpaste brands, Crest, Oral-B and Blend-a-med. This announcement increases the level of recyclability of its toothpaste tubes, as part of the P&G Ambition 2030 commitments of achieving 100% recyclable or reusable packaging.
The leading global oral care brands, Crest and Oral-B, and the European brand Blend-a-med, will start the switch in January 2021 and will continue until full conversion, by 2025.
Toothpaste tubes are used by millions of consumers every day; however, its multi-material construction poses a challenge for recycling facilities around the globe. The solution to this is the HDPE – High-Density Polyethylene – tube, which provides the same product protection as current tubes, and which has been certified by North American and European recycling bodies to be compatible with existing recycling technologies. These HDPE tubes can be recycled where collection programs exist.
For introducing the right solution and making its toothpaste tubes more sustainable, Procter & Gamble is in discussions with several HDPE tube suppliers and has already reached an agreement with Albéa to start using its proprietary Greenleaf Generation 2 tube technology, which enables the tubes to be recyclable wherever collection schemes are active. Greenleaf Generation 2 tubes are recognized by the North American Association of Plastic Recyclers (APR) as well as RecyClass and SUEZ.circpack® in Europe and can be recycled within the existing, effective HDPE bottles recycling stream.
To earn APR recognition, it was demonstrated that the toothpaste tubes could be converted into quality post-consumer HDPE resin, and then reused to make new plastic bottles.
RecyClass is an independent cross-industry platform that assesses material recyclability and provides specific recommendations on how to improve packaging design to fit current recycling technologies in Europe. The platform certifies that Procter & Gamble’s ‘toothpaste tube’ technology is considered to be compatible with HDPE recycling. Moreover, it certifies that both Procter & Gamble’s ‘toothpaste tubes with cap’ product will not have a negative impact on the current European HDPE containers recycling.
“Toothpaste tubes are not largely recyclable today; with the RecyClasscertification for Albéa’s Greenleaf Generation 2 technology used by P&G, however, we are on the right track towards increasing both the design for recycling awareness for tubes as well as increasing recycling quality and rates for the HDPE rigids stream in Europe,” said Paolo Glerean, RecyClass Chairman.
In addition, the sortability of the tubes has been successfully tested by SUEZ.circpack® following the RecyClass sorting protocol, confirming that the tubes will flow into the correct stream and be recycled with the HDPE materials.
“Accurate sorting is an essential step to ensure recycling. That is why SUEZ.circpack® performed sorting tests in a fully operational sorting facility in Germany. The facility and the technologies in place are very common for the European recycling industry. The results showed that the packaging could be correctly sorted into the HDPE material flow. The recognition of the plastic with Near InfraRed (NIR) technology was accurate and consistent,” said Vincent Mooij, Head of SUEZ.circpack®.
“P&G Oral Care started our sustainability journey many years back and continue to reduce our footprint. To drive a more circular supply chain, all of our production sites globally are qualified as sending zero manufacturing waste to landfill, and our sites across the United States, Canada, and Europe purchase 100% renewable electricity,” stated Steve Bishop, P&G Health Care Chief Executive Officer. “There is much yet to be done; however, we are proud of the steps we are taking with our leading brands, Crest in North America, and Oral B and Blend-a-med in Europe, to achieve recyclable tubes in the years ahead.”
Virginie Helias, P&G’s Chief Sustainability Officer added: “We have committed to enable and inspire responsible consumption through innovation on our product and packaging. Our leading oral care brands touch millions of people around the world. This new packaging innovation will contribute to making the toothpaste tubes recyclable at scale in existing recycling streams, hence reducing our footprint and striving for circular solutions. It’s no longer about if or what we can do, but how quickly we can do it.”
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands.
Velvet Gogol Bennett, P&G
Paola Mulas, P&G
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GPD Companies, Inc. to Acquire Distrupol22.1.2021 14:33:00 CET | Press release
GPD Companies, Inc., an affiliate of One Rock Capital Partners, LLC (“One Rock”), today announced that it has entered into a definitive agreement to acquire Distrupol, a subsidiary of Univar Solutions Inc. (NYSE: UNVR) and a leading European distributor of thermoplastics to the polymer processing industry. Terms of the transaction, which is expected to close in the first half of 2021, were not disclosed. Headquartered in Surrey, England, with broad geographic reach across Europe, Distrupol has provided value-added sales and application development of thermoplastic resins for over 50 years. Through its decades-long relationships with world class supply partners, the company offers a robust array of superior performance products and solutions that meet the needs of diverse end users from leading and emerging industries, such as the consumer, medical, automotive, and electrical sectors, among others. Distrupol caters to over 1,300 customers across 13 countries with a portfolio of over 4,0
Schlumberger Announces Fourth-Quarter and Full-Year 2020 Results22.1.2021 12:50:00 CET | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the fourth-quarter and full-year 2020. Fourth-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeDec. 31, 2020Sept. 30, 2020Dec. 31, 2019SequentialYear-on-yearRevenue $5,532 $5,258 $8,228 5% -33%Income (loss) before taxes - GAAP basis $471 $(54) $452 n/m 4%Net income (loss) - GAAP basis $374 $(82) $333 n/m 12%Diluted EPS (loss per share) - GAAP basis $0.27 $(0.06) $0.24 n/m 12% Adjusted EBITDA* $1,112 $1,018 $1,648 9% -33%Adjusted EBITDA margin* 20.1% 19.4% 20.0% 73 bps 6 bpsPretax segment operating income* $654 $575 $1,006 14% -35%Pretax segment operating margin* 11.8% 10.9% 12.2% 90 bps -40 bpsNet income, excluding charges & credits* $309 $228 $545 35% -43%Diluted EPS, excluding charges & credits* $0.22 $0.16 $0.39 37% -44% Revenue by Geography International $4,343 $4,210 $5,834 3% -26%North America 1,167 1,034 2,339 13% -50%Other 22 14 55 n/m n/m $5,532 $5,258 $8,228 5% -33% *These are non-
JEOL: Release of a New Cold Field Emission Cryo-Electron Microscope CRYO ARM™ 300 II (JEM-3300)22.1.2021 07:00:00 CET | Press release
JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new cold field emission cryo-electron microscope (cryo-EM), the CRYO ARM™ 300 II (JEM-3300), to be released in January 2021. This new cryo-EM has been developed based on the concept of "Quick and easy to operate and get high-contrast and high-resolution images". This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005316/en/ Cold Field Emission Cryo-Electron Microscope CRYO ARM(TM) 300 II (JEM-3300) (Photo: Business Wire) Development Background Recent dramatic improvement of resolution in single particle analysis (SPA) using cryo-EM has led to SPA as an essential method for structural analysis of proteins. To address this market, JEOL released the CRYO ARM™ 300 in 2017. Equipped with a cold field emission gun (Cold FEG) for enhanced resolution and a cryo-stage for loading multiple samples, the CRYO ARM™ 300 has continued to achieve best-in-class res
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment21.1.2021 23:12:00 CET | Press release
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is provided as a co-pack with two injectable medicines — ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine— dosed once monthly, as an option to replace the current antiretroviral (ARV) regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiating treatment of Cabenuva, oral dosing of cabotegravir and rilpivirine should be administered for approximately one month to assess the tolerability of each therapy.1 Lynn Baxter, Head of North America, ViiV He
Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)21.1.2021 22:30:00 CET | Press release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The BLA submission is based on data from the Phase 2 POD1UM-202 trial evaluating retifanlimab in previously treated patients with locally advanced or metastatic SCAC who have progressed on, or are intolerant of, standard platinum-based chemotherapy. The trial enrolled 94 patients, including several with well-controlled human immunodeficiency virus (HIV) infection. The study, which was recently presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, resulted in an objective response rate (ORR) of 14% for retifanlimab monotherapy as determined by inde
Wistron and Kalray Announce FURIO1200™ Storage Appliance21.1.2021 17:45:00 CET | Press release
Wistron, a leader in ICT (Information and communications technology) products, and Kalray (Paris:ALKAL) (Euronext Growth Paris: ALKAL), a leading provider in new generation of processors specialized in Intelligent Data Processing from Cloud to Edge, announce the availability of FURIO1200™, a 24-Flash-Drive NVMe-oF based storage node appliance, integrating Kalray’s NVMe-oF K200™ smart storage adapter, powered by its MPPA® Coolidge™ intelligent processor, and Wistron LYMMA chassis. FURIO1200™ is a new type of hyper-fast disaggregated storage solution delivering ultra-high throughput and reliability. It is the ideal solution for Cloud Service Providers and Enterprises running applications with intensive AI and Data Analytics workloads as well as to optimize their next generation storage. Data Centers are undergoing a very important revolution due to the explosion of usages, the surge of data to be processed and the exponential growth of the number of machines to be managed to support this
NumAlim Selects Dawex and Orange Business Services for its Data and Services Exchange Platform21.1.2021 17:40:00 CET | Press release
NumAlim announced an agreement with Dawex, the leader in Data Exchange technology, and Orange Business Services, a network-native digital services company, to deploy its agri-food digital exchange platform. By relying on these two leading players, NumAlim chose secure technological solutions guaranteeing the sovereignty of French food data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005722/en/ (Photo: Dawex) As early as Q1 2021, the NumAlim data and services exchange "Hub" will offer 18,000 companies in the food industry the opportunity to valorize, acquire and enrich all types of data: production, consumption, traceability, consumer opinions and research, as well as a wide range of services based on data (trend analysis, reformulation, regulatory watch…). "NumAlim is the answer to the needs for transparency, value creation and trust expressed by the food industry, consumers, and public authorities.” says Jérôme Fr